articleNature CancerJun 5, 2023HYBRID OA

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

PDL BioPharma (United States) · Roche (Canada) · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

The Hippo pathway is a key growth control pathway that is conserved across species. The downstream effectors of the Hippo pathway, YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif), are frequently activated in cancers to drive proliferation and survival. Based on the premise that sustained interactions between YAP/TAZ and TEADs (transcriptional enhanced associate domain) are central to their transcriptional activities, we discovered a potent small-molecule inhibitor (SMI), GNE-7883, that allosterically blocks the interactions between YAP/TAZ and all human TEAD paralogs through binding to the TEAD lipid pocket. GNE-7883 effectively reduces chromatin accessibility…

Citation impact

188
total citations
FWCI
36.70
Percentile
100%
References
76
Citations per year

Authors

42

Topics & keywords

Keywords
  • Hippo signaling pathway
  • KRAS
  • Allosteric regulation
  • Biology
  • Transcription factor
  • Effector
  • Cancer research
  • Cell biology
UN Sustainable Development Goals
  • Life in Land
No related works found for this paper.